Skip to main content
Download PDF

Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting

Experimental Hematology & Oncology volume 13, Article number: 44 (2024) Cite this article

Abstract

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median progression-free survival of only 3–4 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.

To the editor

Peripheral T-cell lymphoma (PTCL) comprises a heterogeneous group of hematological malignancies where relapsed or refractory (R/R) disease is common. Current standard treatments for R/R PTCL have limited efficacy, and new therapeutic methods are urgently needed [1, 2]. We summarize the latest updates on novel agents and regimens for R/R PTCL from the 2023 ASH Annual Meeting.

Novel agents in R/R PTCL

Valemetostat, a potent dual inhibitor of Enhancers of Zeste Homolog 1 and 2 (EZH1/2), is approved for the treatment of R/R adult T-cell leukemia/lymphoma in Japan. In a multinational pivotal phase II trial of R/R PTCL (VALENTINE-PTCL01), continuous administration of 200 mg/day valemetostat was well tolerated and displayed an objective response rate (ORR) of 43.7% (52/119) with 14.3% complete response (CR) and a median duration of response (DOR) of 11.9 months. Responses were observed across all PTCL subtypes. The median progression-free survival (PFS) and overall survival (OS) were 5.5 months and 17.0 months, respectively [3]. Another exciting EZH1/2 dual inhibitor HH2853 was evaluated in a phase Ib trial. Among 28 R/R PTCL patients with assessable efficacy, HH2853 resulted in a 60.7% ORR with 21.4% CR. With a median follow-up duration of 2.79 months, the median DOR, PFS and OS were not achieved. The 3-month PFS rate and 6-month OS rate were 74.44% and 91.97%, respectively. Trentment-related adverse events (TRAEs) were manageable and consistent with other HH2853 studies [4].

Golidocitinib is the first JAK1 selective inhibitor to enter pivotal clinical development for R/R PTCL. In the global phase II trial (JACKPOT8 Part B), patients with R/R PTCL were given 150 mg/day of golidocitinib continuously and showed a 44.3% (39/88) ORR, including 24% CR, with a median DOR, PFS and OS of 20.7 months, 5.6 months and 19.4 months, respectively. The majority of treatment-emergent adverse events (TEAEs) were reversible and clinically manageable [5].

Linperlisib, a novel PI3Kδ-selective inhibitor, has received marketing approval in China for the treatment of R/R follicular lymphoma patients with 2 prior systemic therapies. In a pivotal phase II study of R/R PTCL, patients were consecutively administered linperlisib 80 mg/day, achieving 48% (42/88) ORR with 30% CR and median PFS and OS of 5.5 months and 14.2 months, respectively. Activity was demonstrated in all subtypes, and the median DOR was not reached at a median follow-up of 13.9 months. Linperlisib has a favorable safety profile, with lower levels of severe gastrointestinal and liver toxicity than other PI3K agents [6]. BR101801, a triple inhibitor of PI3Kγ/δ and DNA-PK, showed clinical benefit and a manageable safety profile in a phase I trial of R/R PTCL: 31.6% (6/19) ORR, 21.1% CR, and a median PFS of 7.5 months; median OS and DOR were not reached in a median follow-up duration of 12.9 months; grade 3–4 TRAEs included elevated transaminases and neutropenia [7].

Preliminary phase Ib data on the anti-KIR3DL2 mAb lacutamab in 10 patients with KIR3DL2-expressing R/R PTCL confirmed an acceptable safety profile for monotherapy, with the majority (90%) of TEAEs being of grade 1–2 severity [8]. The preclinical activity profile improved when assessed in combination with pralatrexate or CHOP. Two additional preclinical studies revealed superior antitumor activity against PTCL with the CD38/CD3xCD28 trispecific antibody SAR442257 monotherapy [9] and the CDK9 inhibitor AZD4573 monotherapy or in combination with CHOP [10].

Novel regimens in R/R PTCL

A multicenter retrospective study of 184 patients with R/R PTCL revealed that novel agent exposure with and without the use of stem cell transplantation (SCT) significantly improved OS and event-free survival [11]. For patients who respond after salvage therapy but are ineligible for autologous SCT or intensive consolidation chemotherapy, a multicenter phase II trial demonstrated that maintenance therapy with the immunomodulator lenalidomide 50 mg for 3 weeks in 4-week cycles was tolerable and produced promising responses, with a 1-year PFS of 49%, a median OS of 34.1 months and manageable TRAEs [12].

The histone deacetylase inhibitor chidamide combined with the hypomethylating agent azacitidine for injection was evaluated in a phase I trial for R/R PTCL. This pair was well tolerated and resulted in an ORR of 56.25% (9/16), with a median PFS and OS of 6.45 months and 17.5 months, respectively [13]. Chidamide has also been studied in combination with parsaclisib, a potent PI3Kδ-selective inhibitor, in a phase Ib/II trial of R/R PTCL. Preliminary results showed a favorable safety profile, with predominantly grade 1/2 hematologic toxicities and gastrointestinal reactions. Among the 9 efficacy evaluable patients, 5 (55.6%) achieved CR, and patients previously exposed to chidamide could still have durable responses [14].

An ongoing phase II study (LuminICE) was designed to explore the efficacy and safety of the CD30/CD16A bispecific antibody (AFM13) in combination with allogeneic natural killer cells (AB-101) in R/R Hodgkin lymphoma and CD30 + PTCL [15].

In conclusion, the 2023 ASH Annual Meeting showcased many notable advances in new agents and novel rational drug combinations targeting the epigenome, proliferative signaling pathways, tumor microenvironment and cell surface receptors for the treatment of R/R PTCL, as summarized in Tables 1 and 2. A deeper understanding of the molecular and genomic profiles will provide potential therapeutic targets for PTCL. Notably, with technological innovations, chimeric antigen receptor (CAR)-T cells targeting CD5, CD7, CD30, CD70 or TRBC1 have been developed and are being explored in clinical trials in selected patients with R/R PTCL.

Table 1 Outcomes of clinical trials of novel agents in relapsed or refractory PTCL from 2023 ASH Annual Meeting
Full size table
Table 2 Outcomes of novel regimens in relapsed or refractory PTCL from 2023 ASH Annual Meeting
Full size table

Data availability

The material supporting the conclusion of this study has been included in the article.

Abbreviations

CAR:

Chimeric antigen receptor

CR:

Complete response

DOR:

Duration of response

EZH1/2:

Enhancers of Zeste Homolog 1 and 2

JAK1:

Janus kinase 1

ORR:

Objective response rate

OS:

Overall survival

PFS:

Progression-free survival

PI3K:

Phosphatidylinositol 3-kinase

PTCL:

Peripheral T-cell lymphoma

R/R:

Relapsed or refractory

SCT:

Stem cell transplantation

TEAE:

Treatment-emergent adverse event

TRAE:

Treatment-related adverse event

References

  1. Xie C, Li X, Zeng H, Qian W. Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma. Exp Hematol Oncol. 2020;9:30.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mulvey E, Ruan J. Biomarker-driven management strategies for peripheral T cell lymphoma. J Hematol Oncol. 2020;13:59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Horwitz SM, Izutsu K, Mehta-Shah N, Cordoba R, Barta SK, Bachy E, et al. Efficacy and Safety of Valemetostat Monotherapy in patients with relapsed or refractory peripheral T-Cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study. Blood. 2023;142:302–302.

    Article  Google Scholar 

  4. Hong H, Zhang M, Peng Z, Shen J, Shuang Y, Zhou H, et al. A multicenter, Open-Label, Single-Arm, phase ib clinical trial of HH2853 in the treatment of patients with relapsed and/or refractory peripheral T-Cell lymphoma. Blood. 2023;142:304–304.

    Article  Google Scholar 

  5. Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: full analysis of the multinational pivotal study results (JACKPOT8). Blood. 2023;142:305–305.

    Article  Google Scholar 

  6. Song Y, Li Z, Wu H, Jin J, Zhou H, Zhou K, et al. A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas. Blood. 2023;142:306–306.

    Article  Google Scholar 

  7. Kim B-S, Kim SJ, Yoon DH, Kim JS, Kim TM, Lee E, et al. A novel PI3K γ/δ and DNA-PK triple inhibitor, BR101801, for r/r PTCL: a phase 1a/b, Multi-center, open-label clinical trial. Blood. 2023;142:1701–1701.

    Article  Google Scholar 

  8. Iyer SP, Ayyappan SR, Greenwell IB, Kim WS, Lee ST, Kim JS, et al. Strategies to develop Anti-KIR Mab Lacutamab in patients with peripheral T-Cell lymphoma: preliminary Monotherapy Clinical Data and Pre-clinical Combinability Data. Blood. 2023;142:3072–3072.

    Article  Google Scholar 

  9. Dupuy A, Pelletier L, Giustiniani J, Kim P, Bisht K, Wang H, et al. The CD38/CD3xCD28 trispecific antibody (SAR442257) potentially represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas. Blood. 2023;142:4384–4384.

    Article  Google Scholar 

  10. Potter DS, Ott I, Saeh J, Olsson R, Fawell S, Drew L, et al. AZD4573 in combination with CHOP increases Combination Benefit in Preclinical Peripheral T-Cell Lymphomas models. Blood. 2023;142:7133–7133.

    Article  Google Scholar 

  11. Tolu SS, Gribbin C, Seshadri MR, Chen Z, Orlando E, Grenet J, et al. Outcomes of contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL. Blood. 2023;142:1698–1698.

    Article  Google Scholar 

  12. Kim SJ, Lee M-W, Lim S-N, Kang K-W, Yoon SE, Lee YJ, et al. Phase II study of Lenalidomide Maintenance after salvage therapy for relapsed or refractory peripheral T-Cell lymphomas. Blood. 2023;142:3073–3073.

    Article  Google Scholar 

  13. Yu J, Lu Y, Yao Y, Liu X, Li L, Qian Z, et al. Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: a phase I study. Blood. 2023;142:3076–3076.

    Article  Google Scholar 

  14. Yan Z, Yao S, Zhao S, Wang H, Chu J, Xu Y, et al. Selective PI3Kδ inhibitor parsaclisib combined with HDAC inhibitor chidamide in patients with Relapsed/Refractory peripheral T-Cell lymphoma: preliminary results of a phase Ib/II study. Blood. 2023;142:3075–3075.

    Article  Google Scholar 

  15. Moskowitz A, Harstrick A, Emig M, Overesch A, Pinto S, Ravenstijn P, et al. AFM13 in combination with allogeneic natural killer cells (AB-101) in relapsed or refractory Hodgkin Lymphoma and CD30 + peripheral T-Cell lymphoma: a phase 2 study (LuminICE). Blood. 2023;142:4855–4855.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study is supported by the National Natural Science Foundation of China (No. 82,003,196 and 82,270,198), the Cancer Innovative Research Program of Sun Yat-sen University Cancer Center (No. CIRP-SYSUCC-0022), the Outstanding Young Scientific and Technological Talents Fund of Sichuan Province (No. 2022JDJQ0059), and Medical Science and Technology Foundation of Guangdong Province (No. A2021426).

Author information

Author notes

  1. Huageng Huang MD, Wei Zhang MD and Xinyi Deng MM contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China

    Huageng Huang, He Huang, Zhao Wang & Tongyu Lin

  2. Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, 610000, Sichuan, China

    Wei Zhang & Huangming Hong

  3. Department of Dermatology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China

    Xinyi Deng

Authors
  1. Huageng Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xinyi Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. He Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huangming Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tongyu Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HGH, WZ and XYD conceptualized the manuscript. HGH prepared the tables. All authors participated in the process of drafting and revising the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Huangming Hong or Tongyu Lin.

Ethics declarations

Ethics approval and consent to participate

Not Applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, H., Zhang, W., Deng, X. et al. Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting. Exp Hematol Oncol 13, 44 (2024). https://doi.org/10.1186/s40164-024-00510-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40164-024-00510-w

Keywords

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us